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Abstract: The pharmacokinetics of cefepime was studied in 5 goats following i.v. and i.m. administration of 10 mg/kg of
body weight. Following i.v. administration, the cefepime plasma concentration-time curves were best fitted in a onecompartment open model. The elimination half-life (t1/2β), area under curve (AUC0→∞), and total body clearance (ClB)
were 1.86 ± 0.54 h, 181.58 ± 80.52 μg.h/mL, and 1.10 ± 0.54 mL/min/kg, respectively. Following i.m. administration,
pharmacokinetic parameters were analyzed using statistical moment theory (SMT). The drug was absorbed rapidly, with
an absorption half-life (t1/2abs) of 0.77 ± 0.34 h. The peak plasma concentration (Cmax) of 49.32 ± 10.33 μg/mL was attained
after (Tmax) 0.80 ± 0.11 h, with an elimination half-life (t1/2β) of 1.65 ± 0.38 h. The systemic bioavailability (F) of cefepime
in the goats after i.m. administration was 86.45 ± 17.39% and in vitro plasma protein binding was 7.45 ± 4.46%. The
dosage regime was estimated via the PK-PD relationship, considering the t>MIC value. The results suggest that cefepime
was a potential bactericidal agent for more than 7 h by both administration routes, and that it might be very useful in
the treatment of various infections in goats at 10 mg/kg of body weight administered i.v. or i.m. with 10 h as the dosage
interval.
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Introduction
Cefepime is a semi-synthetic, parenteral fourthgeneration cephalosporin antibiotic with significant
potential advantages over other broad-spectrum
cephalosporins (1). It is non-susceptible to β-lactam

hydrolysis. Cefepime shows excellent activity against
Escherichia coli, Klebsiella pneumoniae, Pseudomonas
aeruginosa, Enterococcus clocae, Staphylococcus
aureus, and Streptococcus spp., and is considered a
broad spectrum antibiotic (2). The efficacy of
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cephalosporins is estimated via the PK-PD
relationship to prevent the problem of bacterial
resistance. When MIC remains 40%-60% above the
inter-dose interval, better therapeutic results with
low-level resistance have been observed (3).
The pharmacokinetic profile of cefepime has been
studied in rats and monkeys (4), humans (5), horses
(6), foals and dogs (7), cow calves (8), and buffalo
calves (9). The objective of the present study was to
explore further the therapeutic potential of cefepime
in goats following i.v. and i.m. administration, and to
estimate the dosage regimen in consideration of the
PK-PD relationship.
Materials and methods
Drugs and experimental animals
Cefepime hydrochloride powder (Megapime®,
Alkem Ltd., Mumbai, India) was diluted with sterile
distilled water to 10% immediately before
administration. The experiment was conducted using
healthy goats (n = 5) aged 1.5-3 years with a body
weight between 30 and 47 kg. The animals were
procured from the Department of Sheep Husbandry,
Jammu (J & K, India). One month before the
experiment all the animals were de-wormed with
mebendazole and acclimatized to their new
environment. Water was provided ad libitum.
Experimental design
A 2-way crossover design was applied with a
washout period of 20 days between treatments.
Cefepime was administered at 10 mg/kg of body
weight i.v. for intravenous study. In the second part of
experiment cefepime at 10 mg/kg of body weight was
administered i.m. for intramuscular study. The i.v.
injection was administered in the v. jugularis and the
i.m. injection in the thigh muscle. Blood samples (4
mL) were collected into heparinized tubes from the
contra-lateral v.jugularis prior to injection and at 0.08,
0.16, 0.33, 0.50, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h
after administration. Plasma was separated after
centrifugation at 1000´g for 15 min and stored at -20
°C until analysis.
Cefepime analysis
Plasma cefepime concentrations were measured
using the agar-plate diffusion method (10,11) with the
428

test microorganism Escherichia coli MTCC 443 and
assay media No. 1 (HiMedia, Mumbai, India).
Cefepime standard solution was prepared in
antibiotic-free goat’s plasma at concentrations ranging
from 0.2 to 50 μg/mL and a standard curve was
obtained with the correlation coefficient r > 0.98. The
minimal quantification level of the assay method was
0.2 μg/mL. Intra-assay precision was determined by
measuring 6 replicates of representative standard
concentrations prepared in plasma. The coefficient of
variation was <5.54% and <9.66% for the intra-assay
and inter-assay, respectively.
Pharmacokinetics analysis
Pharmacokinetic analysis of the data was
performed by compartmental and noncompartmental methods using the TopFit v.2.0
pharmacokinetic computer program (12). The best fit
was determined according to the Akaike Information
Criterion (AIC) (13). A non-compartmental analysis
based on statistical moment theory was also carried
out (14). The area under the concentration-time curve
(AUC0→∞, AUC0→12 h) was calculated via the trapezoidal
method (15). The peak plasma concentration (Cmax)
and the time to reach maximum concentration (Tmax)
were obtained from the plasma concentration-time
curve of each animal. The absolute bioavailability
after i.m. administration was calculated using the
equation F = (AUCi.m./AUCi.v.) × 100.
Plasma protein binding
In vitro plasma protein binding of cefepime was
determined according to the method described by
Craig and Suh (16), using pooled plasma from the
goats and phosphate buffer (pH 7.9 ± 0.1). The
percentage of the protein-bound fraction was
calculated using the following equation: protein
binding % = (zone of inhibition in buffer - zone of
inhibition in plasma/zone of inhibition in buffer) ×
100.
Results
The drug concentration vs. time curves after i.v.
injection was best fitted in a one-compartment open
model. Following i.m. administration, plasma
concentration data were analyzed using the noncompartmental method based on statistical moment
theory.

The Table summarizes the pharmacokinetic
parameters for cefepime following i.v. and i.m.
administration. The drug was detected in goat plasma
up to 12 h following i.v. and i.m. administration
(Figure). The last detectable limit of the drug in
plasma at 12 h for i.v. and i.m. routes of
administration was 0.33 ± 0.10 μg/mL and 0.34 ± 0.17
μg/mL, respectively. Plasma protein binding varied
from 3.09% to 13.82%, with a mean ± SD value of 7.45
± 4.46%. Plasma protein binding was independent of
cefepime concentrations.

Concentrations (µg/mL)
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Figure. Plasma concentrations (mean ± SD) of cefepime in goats
following single i.v. and i.m. administration at 10 mg/kg
body weight (n = 5).

Discussion
Following i.v. administration of cefepime in the
present study, the elimination half-life was lower than
that in buffalo calves (t1/2β =2.67 h) (9), higher than
that in dogs (t1/2β =1.09 h) (7), and similar to that in
ewes (t1/2β=1.76 h) (17). Mean residence time (MRT)
after i.v. and i.m. administration was shorter than that
in rabbits (MRT = 3.65 h) (18) and calves (MRT =

3.38 h, MRT = 3.95 h) (8,19), and longer than that in
ewes (MRT = 2.28 h) (17). The ClB (1.10 ± 0.54
mL/min/kg) value following i.v. administration was
lower than that in dogs (ClB = 2.20 mL/min/kg) (7)
and similar to that in calves (ClB = 1.10 mL/min/kg)
(8). The t1/2β, MRT, and AUC0→∞ values for the 2 routes
(i.v. and i.m.) were similar (Table).

Table. Pharmacokinetic parameters (n = 5) of cefepime following single i.v. and i.m. injection in
goats at 10 mg/kg of body weight (mean ± SD).

Pharmacokinetic
parameters
t1/2β

Compartmental
analysis

Non-compartmental
analysis

intravenous

intramuscular

1.86 ± 0.54

1.65 ± 0.38

Units

h
h

2.70 ± 0.80

2.39 ± 0.30

AUC0→12h

μg.h/mL

173.97 ± 75.66

156.11 ± 0.04

AUC0→∞

MRT

μg.h/mL

181.58 ± 80.52

156.98 ± 44.50

Vc

L/kg

0.14 ± 0.07

-

ClB

mL/min/kg

1.10 ± 0.54

-

t1/2abs.

h

-

0.77 ± 0.34

Cmax

μg/mL

-

49.32 ± 10.33

Tmax

h

-

0.80 ± 0.11

F

%

-

86.45 ± 17.39

t1/2β-elimination half-life, MRT-mean residence time,
t1/2abs-absorption half-life,
AUC0→12-area under the plasma concentration vs. time curve from 0 to 12 h,
AUC0→∞-area under the plasma concentration vs. time curve from 0 to ∞,
Vc-apparent volume of central compartment, ClB-total body clearance,
Cmax-peak drug concentration,
Tmax-time to reach peak concentration,
F-Bioavailability.
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Following i.m. injection of cefepime, Cmax was
49.32 ± 10.33 μg/mL at 0.80 h, which is in agreement
with that reported by Joshi and Sharma (9) in buffalo
calves. The drug was absorbed rapidly from thigh
muscles (t1/2abs = 0.77 ± 0.34 h). The t1/2β and MRT
values in the present study following i.m.
administration were lower than those reported in
calves (t1/2β = 3.03 h, MRT = 4.72 h) (8).
The absolute bioavailability (F) observed in the
present study indicates that there was very good
absorption of the drug from the i.m. injection site (F
= 86.45%). This value is similar to that reported in
ewes (F = 86.8%) (17) and lower than that in calves (F
= 95.7%) (8). A primary determinant of antibacterial
activity for β-lactam antibiotics is t>MIC (20,21). The
time above MIC was estimated from the plasma
concentration versus time curve (Figure) and was
expressed as a percentage of the inter-dose interval. A
t>MIC of 35%-40% and an inter-dose interval of 60%70% for cephalosporin have been established as
optimal for bacteriostatic and bactericidal effect,

respectively (22,23). For cefepime the MIC against the
majority of gram-positive and gram-negative
pathogens has been reported to be ≤1 μg/mL (24,25).
The MIC for both routes of administration in the
present study was 2.5-fold greater than the 70% of
dosage interval (7 h). This supports the fact that
cefepime is a potential bactericidal agent for more
than 7 h following i.v. and i.m. administration. This
finding is in agreement with that reported by Ismail
(17) in ewes. The findings of the present study
indicate that cefepime might be very useful in the
treatment of various infections in goats at the dose
rate of 10 mg/kg of body weight and 10 h as the
dosage interval when administered by i.v. or i.m.
routes. In the present study cefepime was selected as
a drug for the following reasons: i) to overwhelm
resistant organisms, ii) to treat mixed-type infections,
iii) to treat infections in tissues in which the reach of
conventional cephalosporins is restricted, and iv) to
obtain basic data concerning the drug’s dosage
regimen in goats.

References
1.

2.

3.

4.

5.

6.

430

7.

Gardner, S.Y., Papich, M.G.: Comparison of cefepime
pharmacokinetics in neonatal foals and adult dogs. J. Vet.
Pharmacol. Ther., 2001; 24: 187-192.

8.

Barradell, L.B., Bryson, H.M.: Cefepime. A review of its
antibacterial activity, pharmacokinetic properties and
therapeutic use. Drugs, 1994; 47: 471–505.

Ismail, M.M.: Disposition kinetics, bioavailability and renal
clearance of cefepime in calves. Vet. Res. Commun., 2005; 29:
69-79.

9.

McKellar, Q.A., Sanchez Bruni, S.F., Jones, D.G.:
Pharmacokinetic/pharmacodynamic
relationships
of
antimicrobial drugs used in veterinary medicine. J. Vet.
Pharmacol. Ther., 2004; 27: 503-514.

Joshi, B., Sharma, S.K.: Pharmacokinetic disposition and
bioavailability of cefepime in buffalo calves. J. Vet. Pharmacol.
Ther., 2007; 30: 500-502.

10.

Simon, H.J., Yin, E.J.: Microbioassay of antimicrobial agents.
Appl. Microbiol., 1970; 19: 573-579.

11.

Arret, B., Johnson, D.P., Kirshbaum, A.: Outline of details for
microbiological assay of antibiotics: second revision. J. Pharm.
Sci., 1971; 60: 1689-1694.

12.

Barbhaiya, R.H., Knupp, C.A., Forgue, S.T., Matzke, G.R.,
Halstenson, C.E., Opsahl, J.A., Pittman, K.A.: Disposition of the
cephalosporin cefepime in normal and renally impaired
subjects. Drug Metab. Dispos., 1991; 19: 68-73.

Heinzel, G., Woloszczak, R., Thomann, P.: TopFit. Version 2.0,
Pharmacokinetic and Pharmacodynamic Data Analysis System
for the PC. Gustav Ficher, Stuttgart, Jena, New York. 1993.

13.

Guglick, M.A., MacAllister, C.G., Clarke, C.R., Pollet, R., Hague,
C., Clarke, J.M.: Pharmacokinetics of cefepime and comparison
with those of ceftiofur in horses. Am. J. Vet. Res., 1998; 59: 458463.

Yamaoka, K., Nakagawa, T., Uno, T.: Application of Akaike,s
information criterion (AIC) in the evaluation of linear
pharmacokinetic equations. J. Pharmacokinet. Biopharm., 1978;
6: 165-175.

14.

Gibaldi, M., Perrier, D.: Non-compartment analysis based on
Statistical Moment Theory. In: Pharmacokinetics. 2nd edn.,
Marcel Dekker, Inc. New York, USA. 1982; 409-424.

Kessler, R.E., Bies, M., Buck, R.E., Chisholm, D.R., Pursiano,
T.A., Tsai, Y.H., Misiek, M., Price, K.E., Leitner, F.: Comparison
of a new cephalosporin, BMY 28142, with other broadspectrum β-lactam antibiotics. Antimicrob. Agents Chemother.,
1985; 27: 207-216.

Forgue, S.T., Shyu, W.C., Gleason, C.R., Pittman, K.A.,
Barbhaiya, R.H.: Pharmacokinetics of the novel cephalosporin
cefepime (BMY-28142) in rats and monkeys. Antimicrob.
Agents Chemother., 1987; 31: 799-804.

S. PRAWEZ, R. RAINA, D. DIMITROVA, N. K. PANKAJ, A. A. AHANGER, P. K. VERMA

15.

Baggot, J.D.: Principles of Drug Disposition in Domestic
Animals: The Basis of Veterinary Clinical Pharmacology. 1st
edn., W.B. Saunders, Philadelphia, USA. 1977; 144-189.

16.

Craig, W.A., Suh, B.: Protein binding and antibacterial effects;
Methods for determining protein binding. In: Lorian, V., Ed.
Antibiotics in Laboratory Medicine. Williams & Wilkins,
Baltimore, London. 1980; 265-297.

17.

Ismail, M.M.: Pharmacokinetics of cefepime administered by
i.v. and i.m. routes to ewes. J. Vet. Pharmacol. Ther., 2005; 28:
499-503.

18.

Goudah, A., Mouneir, S.M., Shim, J.H., Abd El-Aty, A.M.:
Influence of endotoxin induced fever on the pharmacokinetics
of intramuscularly administered cefepime in rabbits. J. Vet. Sci.,
2006; 7: 151-155.

19.

Patel, U.D., Bhavsar, S., Thaker, A.M.: Pharmacokinetics and
dosage regimen of cefepime following single dose intravenous
administration in calves. Iranian J. Pharmacol. Ther., 2006; 5:
127-130.

20.

Craig, W.A.: Interrelationship between pharmacokinetics and
pharmacodynamics in determining dosage regimens for broad
spectrum cephalosporins. Diagn. Microbiol. Infect. Dis., 1995;
22: 89-96.

21.

Turnidge, J.D.: The pharmacodynamics of β-lactams. Clin.
Infect. Dis., 1998; 27: 10-22.

22.

Hyatt, J.M., McKinnon, P.S., Zimmer, G.S., Schentag, J.J.: The
importance of pharmacokinetic/pharmacodynamic surrogate
markers to outcome. Focus on antibacterial agents. Clin.
Pharmacokinet., 1995; 28: 143-160.

23.

Toutain, P.L., del Castillo, J.R.E., Bousquet-Mélou, A.: The
pharmacokinetic-pharmacodynamic approach to a rational
dosage regimen for antibiotics. Res. Vet. Sci., 2002; 73: 105-114.

24.

Prescott, J.F., Baggot, J.D., Walker, R.D.: “β-lactam antibiotics:
Cephalosporins. In: Prescott, J.F., Baggot, J.D., Walker, R.D.,
Eds., Antimicrobial Therapy in Veterinary Medicine, 3rd edn.,
Iowa State University Press/Amess, Ames, Iowa, USA. 2000;
139-157.

25.

Pichardo, C., Rodríguez-Martínez, J.M., Pachón-Ibañez, M.E.,
Conejo, C., Ibáñez-Martínez, J., Martínez-Martínez, L., Pachón,
J., Pascual, A.: Efficacy of cefepime and imipenem in
experimental murine pneumoniae caused by porin-deficient
Klebsiella pneumonia producing CMY-2 β-lactamase.
Antimicrob. Agents Chemother., 2005; 49: 3311-3316.

431

